Supplemental Figure Legends

Rational for step:
Although CAD occurs in the arterial wall, well established risk factors for CAD are primarily caused by molecular defects reflected by gene expression in key metabolic organs, like the liver, skeletal muscle and fat tissue.
Dataset: STAGE consists of seven vascular and metabolic tissues, which were sampled during coronary artery bypass grafting from more than 100 patients, resulting in a total of 612 RNA samples from which gene expression data was generated using custom Affymetrix array (HuRSTA-2a520709) from atherosclerotic arterial wall (AAW, n = 73), internal mammary artery (IMA, n = 88), liver (n = 87), skeletal muscle (SM, n = 89), subcutaneous fat (SF, n = 72), visceral fast (VF, n = 98) and fasting blood (n=105). Whole blood was also used for isolation of DNA (n = 109) for genotype analysis using the Affymetrix GenomeWideSNP_6 arrays and for biochemical analyses.
Outcome of this step: After normalization and quality control, expression levels for 19,610 unique genes across 612 tissue samples and genotype values for 530,222 autosomal SNPs across 109 individuals were available for downstream analysis.
Methods and statistical thresholds:
To validate and further filter the 30 CAD-causal RGNs, we assessed CADrelated mouse phenotype-eigengene correlations using gene expression levels for mouse orthologs to the human module genes in corresponding mouse tissues using the hybrid mouse diversity panel (HMDP) dataset.
Outcome of this step:
Out of 26 CAD-causal RGNs associated with the extent of atherosclerosis, plasma levels of cholesterol or glucose (the CRP phenotype was not available in the HMDP and was therefore not validated), 12 CAD-causal RGNs were validated using the HMDP datasets, of which 3 for extent of atherosclerosis (RGNs 42, 58, 98) .
(G) siRNA targeting of key drivers in THP-1.
Rational for step:
Foam cell formation is central to all steps of atherosclerosis development. We therefore sought to validate the key drivers of the three cross-species-validated atherosclerosis-causal RGN modules (RGNs 42, 58, 98) using siRNA in human THP-1 monocytes differentiated into macrophages and incubated with acetylated-LDL to form foam cells.
Methods and statistical thresholds:
First to test whether the network modules are active in THP-1 macrophages, we screened THP-1 macrophage RNA isolated after siRNA targeting of the key drivers using custom microarrays (left). Then if a KD was found to specifically activate its RGN in the THP-1 macrophages, it was also assessed whether siRNA targeting of this key drivers affected THP-1 foam cell formation in vitro as measured by cholesterol-ester accumulation (right).
Outcome of this step:
Only RGN 42 with four of its key drivers (AIP, DRAP1, POLR2I, and PQBP1) were found active in THP-1 macrophages and affect foam cells formation.
Figure S2. Related to Figure 2 and 3. RGNs of Cholesterol Modules Causally Related to CAD
RGNs including key drivers and main functional enrichments inferred from genes in each of the ten cholesterol modules found to be causal for CAD are shown (Panels A-J).
(A) MODULE 20: This AAW-specific LDL-related and immune process enriched RGN (n = 205) insulin . OF these, GUCY1A/B3 were also key drivers together with ABLIM3, GFI1B, LY6G6F, MFAP3L, PTCRA and TAL1 primarily involving coagulation and vasodilation processes. The regulatory eQTLs of this RGN were also found to be highly enriched in association with levels of LDL (2.4 fold, p = 3.8 x 10 -18 ) and HbA1c (2.7 fold, p = 3.5 x 10 -26 ).
(C) MODULE 87: This SF dominated, CAD-association enriched RGN (n = 57) also with arterial wall genes (8 from the AAW and 1 from IMA) involving immune response genes, related to total plasma cholesterol levels had one GWA gene (CR2 T2DM ) and with the key drivers CHRNA3, PRSS16 and SPRR1B individually implicated in nicotine dependence (Greenbaum et al., 2009) , insulin dependence (Cheunsuk et al., 2002) and induction of apoptosis (Gleyzer and Scarpulla, 2013) , respectively.
(D) MODULE 95: This immune process-related, CAD association-enriched RGN (n = 52) was found active in VF with the key driver KLF1.
(E) MODULE 99: This SM-specific LDL-cholesterol related RGN (n = 49) contained the GWA gene LPL CAD and the key drivers ASB15, IRX5 (counteracts CXCL12 known to protect against myocardial infarction) and IRF6 regulating genes involved in lipid and lactate processing as well as ubiquitin-proteasome system for the degradation of proteins.
(F) MODULE 100: The SF-specific, HDL-related RGN (n = 47) found to be entirely dominated by the key driver MESP1, previously implicated in congenital heart disease (Lahm et al., 2013) .
(G) MODULE 111: This SF dominated RGN (n = 41) containing 4 liver genes enriched with genes related vascular smooth muscle contraction with the key drivers, C22orf34 and HOXD3 together with the GWA gene EDNRA CAD . Whereas EDNRA is a potent vasoconstrictor, HOXD3 overexpression in mice has shown to induce cell adhesion genes like intergrins (Hamada et al., 2001) .
(H) MODULE 138: The AAW-specific HDL-cholesterol related RGN (n = 30) was found to contain the GWA CAD gene TRIB1 CAD as a key driver together with NR4A2 and SIK. The latter key drivers are a steroid-thyroid hormone-retinoid receptor linked to Parkinson and a serine/threonine-protein kinase involved in various processes including regulation of gluconeogenesis and lipogenesis. TRIB1 is believed to interact and regulate the activation of MAP kinases.
(I) MODULE 152: This RGN was generally enriched with genes involved in regulating cell death. The SF-specific, LDL-related RGN (n = 26) contained 2 key drivers SOX10 and FHL5 with high-hierarchical regulatory roles in embryonic development enriched with genes involved in collagen and extracellular matrix rearrangement.
(J) MODULE 156: This small SM-specific LDL-cholesterol and plasma insulin related RGN (n = 24) containing the GWA gene, KIAA1462
CAD with yet unknown function and the key drivers, DDX60 and MAN1A1 with antivirus and glycosyl hydrolases functions, respectively. RGNs including key drivers and main functional enrichments inferred from genes in each of the five glucose modules found to be causal for CAD are shown (panels A-E).
(A) MODULE 64: This multi-tissue pro-insulin related RGN (n = 62/78) dominated by SF genes (n = 34) but present in all tissues (with at least 2 genes) was found to have the highest enrichment for CAD-association (12.7 fold, p < 1.0 x 10 -300
). This RGN was also found to contain 3 GWA genes whereof PLTP
HDL , STAB1
HDL and CDKN2A CAD (also found as a key driver in the VF RGN of Figure 3F and a candidate gene for the chr9 GWA locus) is together with key 3 drivers CLEC10A, FOXD1 and SIX2 regulating innate immune response and regulation of T-cell proliferation genes among others.
(B) MODULE 69: This pro-insulin related but AAW near-specific RGN (n = 72) including the key drivers genes CEBPA, HMGA1 and GAS7 was found to contain genes involved in apoptosis.
(C) MODULE 112: This small multi-tissue, pro-insulin-related RGN (n = 22/40) dominated by liver genes was found to contain the well-established CAD GWA genes, LDLR CAD,TC,LDL and CETP TC,TG,LDL,HDL and the less known C9orf47 together with PRINS (a non-coding stress induced transcript associated with psoriasis) , and key drivers EMR1 and HCG27, the latter also indicated as a CAD GWA gene (Davies et al., 2012) . This RGN was also enriched in CAD-association (2.9 fold, p = 2.7 x 10 -19 ) and in association with plasma HDL (2.5 fold, p = 6.3 x 10 -12 ) and triglycerides (3.3 fold, p = 1.4 x 10 -24
) levels and contained genes generally involved in trans-membrane signaling (e.g., clathrin-coated endocytic vesicle transport) and complement components.
(D) MODULE 129: This SF-specific, pro-insulin related RGN (n = 32) was found to contains genes involved in organ morphogenesis and the key drivers IRX3, IRX5 and SHOX. IRX3 has been associated with the FTO gene and susceptibility for obesity (Smemo et al., 2014) , IRX5 gives rise to sever developmental disorders and SHOX to short stature (Sawada et al., 2015) .
(E) MODULE 140: a small multi-tissue pro-insulin and insulin-related RGN (n = 21/30) dominated by VF genes with the CAD GWA gene LIPA (also a key driver in the RGN of Figure S2A ) as its only key driver regulating genes involved in carboxylic ester hydrolase activity. ) involved genes in tissue development (Table S2 ) and has 18 key drivers (CDH1, TTC39B, KLF5, TP63, TEF, HOXA4, IRF6, SALL2, BCL11A, TRIM29, ISL1, OBSCN, FOXG1, HOXD8, HOXB3, VASN, GSC, and HOXA5) (B) MODULE 89: This SM-specific, CRP related RGN (n = 56) was found enriched in CAD association (2.8-fold). Genes in this network and their key driver AEBP1 involved extracellular matrix organization (Table S3 ).
(C) MODULE 90: This VF-specific, CRP-related RGN (n = 56) was found enriched in CAD association (2.7-fold) and contain 1 GWA genes (CELSR2 LDL,TC ) to involving genes regulating angiotensin levels in blood (Table S3 ). The key drivers of this network are IRX5, HOXB8, PAX3 and SHOX2.
(D) MODULE 148: This near SF-specific RGN (n = 27 and 1 from AAW) was found enriched in CAD association (2.7-fold) and involve genes related to leukocyte migration. The key drivers were RAC2 and EAF2. RGNs including key drivers and main functional enrichments inferred from genes in each of the three CAD-causal modules found to be associated with more than one of the four CAD phenotypes are shown (panels A-C).
(A) MODULE 27: A multi-tissue insulin-and LDL cholesterol-related RGN (n = 165/166) dominated by SF genes (A) was highly enriched in CAD/MI risk (6.6 fold, p = 1.2 x 10 -145 ) and type-2 diabetes (3.7 fold, p = 4.5 x 10 -34 ). In addition, this RGN contains 2 GWA genes, GUCY1B3 CAD (also a key driver in the SM RGN in Figure S2B ) and SOX17 LDL,TC both found to be key drivers together with TAL1 (also a key driver in the SM RGN in Figure S2B ), TBX2, HEY1, HOXD1, MEOX2 and SOX7 regulating genes in vascular development/angiogenesis.
(B) MODULE 36: This SM-specific, total plasma cholesterol-and fasting glucose-related RGN (n = 137) was found to contain 5 GWA candidate genes (EDNRA CAD , FLT1 CAD , GUCY1B3 CAD (a key driver in Figure S2B and S5A), HHEX T2DM , and SOX17 LDL,TC (a key driver in FigureS5A)) whereof FLT1 also was identified as a key driver together with FL1, LDB2, MECOM, TAL1 (also a key driver in Figure S2B and FigureS5A) and TBX2 (also in FigureS5A) involving genes in vascular angiogenesis, trans-endothelial leukocyte migration and endothelial integrity and development.
(C) MODULE 105: This SF-specific, insulin-and CRP-related RGN (n = 44) containing one GWA gene, VAMP8
CAD also identified as a key driver together with CD86 (also a key driver in the AAW-specific RGN in Figure S2A ) and RNASE6 regulating genes involved in immune system processes. 
Supplemental Tables (in Word Format)
Table S6. Related to Figure 3 and Experimental Procedures. Connectivity of RGN Genes Inferred from Module 1 to 171
Source and target genes of all RGNs with interaction score, is the frequency of occurrence of an edge across multiple runs of the bayesian network search algorithm. Module 114 and 137 has no RGN since they do not have any of TF/eQTL/CAD candidate genes (see section on "Bayesian Regulatory-Gene Network Reconstruction" above).
Supplemental Experimental Procedures The STAGE Genetics of Gene Expression Study
In the STAGE study, seven vascular and metabolic tissues of well-characterized CAD patients were sampled during coronary artery bypass grafting surgery (Hägg et al., 2009) . Eligible patients gave written consent to participate (Dnr 004-02). Exclusion criteria were other severe systemic diseases. Tissue samples were obtained from atherosclerotic arterial wall (AAW), internal mammary artery (IMA), liver, skeletal muscle (SM), subcutaneous fat (SF), and visceral fat (VF) and stored at -80 ˚C in RNAlater (Ambion). In brief and as previously described (Hägg et al., 2009) , AAW was obtained from 1-3 puncture biopsies of the atherosclerotic aortic root (Nafakhi et al., 2015) made in CABG to allow ligating the proximal ends of the vein grafts. Non-atherosclerotic arterial wall was from the internal mammary artery ((IMA) routinely used as the anastomosis for the left anterior descending (LAD) artery). With some margin the IMA is dissected free on the inside of thorax next to the sternum, and the distal end was used for RNA isolation. For reasons still largely unknown (Otsuka et al., 2013 ) advanced lesions do not develop in the internal mammary artery, which apart from early "fatty streak" lesions, remains largely atherosclerosis-free. In the STAGE study, the absence of atherosclerotic lesions was confirmed by macroscopic and occasional microscopic examinations of internal mammary artery samples before RNA isolation. In random control biopsies, Oil-Red-O lipid staining followed by microscopic examination again revealed no atherosclerotic lesions, although fatty streaks were at times observed. Subcutaneous fat was obtained from the initial incision longitudinal to the sternum, skeletal muscle from the m. rectus cranial section, visceral fat from pericardial fat, and the liver through a small incision in the diaphragm (Ethical approval #002-04, Karolinska Hospital). Patients were examined, and fasting blood (for DNA, RNA isolations, and biochemistry) was obtained preoperatively. DNA samples were obtained from blood and together with RNA samples isolated with Qiagen Mini/Midi-Kit (Ambion). DNA from 109 patients with sufficient quantities and qualities (≥ 1 µg, 1.7 > 260/280 > 1.9 with Nanodrop, Agilent) were genotyped with the GenomeWideSNP_6 array (Affymetrix). Allele frequencies for 909,622 single nucleotide polymorphisms (SNPs) were determined with the Birdseed algorithm in Affymetrix Power Tools (v 1.14.2); 530,222 autosomal SNPs with call rates of 100% and minor allele frequency > 5% and in Hardy-Weinberg equilibrium (p > were used for downstream analysis (the "QC SNP set") (Foroughi Asl et al., 2015) . Custom-made HuRSTA-2a520709 arrays (Affymetrix) were used for gene expression profiling of total RNA samples (≥5 µg, 1.95 > 260/280 > 2.05 with Nanodrop, Agilent) from 121 patients (AAW, n = 73; IMA, n = 88; liver, n = 87; SM, n = 89; SF, n = 72; VF, n = 98 and blood, n = 105) according to the manufacturer's instructions. Robust multi-array average was used for background subtraction, normalization, and summarizing of raw microarray data (Affymetrix Power Tools, v 1.14.2). A custom-made Chip Description File (CDF) was used to match 381,707 probes on the array to 19,610 probe sets for unique genes (to avoid cross-hybridization between alternative transcripts) according to the hg19 human genome assembly.
Phenotypic measurements (mostly standard plasma measures) were collected as previously described (Hägg et al., 2009) . To determine the extent of atherosclerosis, all CABG patients underwent preoperative biplane coronary angiography (Judkins technique). Angiograms were evaluated with QCA techniques (Medis). The left and right coronary arteries and their branches were divided into segments (Austen et al., 1975) . Each segment was measured during end-diastole. Two scores were calculated:
(1) The stenosis score measures the stenosis in each patient and calculates the percentage diameter stenosis (%DS), the reduction in lumen diameter caused by the plaque (see figure below) . Stenosis was categorized as mild or severe, as shown below. A total occlusion is 100 %DS. The score is calculated as 1 x #mild stenosis + 2 x #severe stenosis.
(2) The segment area score measures the amount of atherosclerosis in all the vessels in a patient. The measurement is the total percentage of plaque area in a segment (see figure below). To be able to get obtain a final score, the average percent stenosis over all the segments is calculated.
Cross-Tissue Weighted Gene Co-Expression Network Construction
First, the most variably expressed genes with standard deviation > 0.5 were selected, resulting in 3,369 (AAW), 2,761 (IMA), 1,588 (liver), 2,492 (SM), 3,596 (SF), 5,215 (VF) and 1,891 (blood) genes per tissue. Next, we used the weighted gene co-expression network analysis (WGCNA) method (Zhang and Horvath, 2005) to construct cross-tissue (CT) co-expression gene networks. WGCNA constructs an adjacency matrix A between every pair of expression traits, defined by A ij = |C ij | β , where C ij is the Pearson correlation coefficient between traits i and j, and β is a parameter determined in such a way that the resulting network is approximately scale-free. In a CT network, each expression trait corresponds to gene-tissue pair (Dobrin et al., 2009; Zhang et al., 2013) . The Pearson correlation coefficient between two traits in different tissues can be calculated using the subset of patients who donated samples from both tissues (the number of available samples in each tissue as well as subsets of samples available in each pair of tissues are shown in Table S8 ).
In doing so, a significant difference between the distribution of tissue-specific (TS) and CT correlation coefficients was noted, with the latter shifted towards lower absolute values. As a result, when we fitted a single value of β to the entire correlation coefficient matrix C, the TS networks were, as expected, scale-free with sufficient total strength of connectivity (with recommended default value β = 6, the average scale-free fit score for TS networks was R 2 = 0.80 and the average total TS connectivity (= sum of adjacency values) per gene 54.10). However, the CT networks were not found to be scale-free and had insufficient total strength of connectivity (average R 2 = 0.66 and average total CT connectivity = 0.73, i.e. less than one CT edge per gene on average). Here, R 2 is the fitting index of the linear model which regresses log P(k) on log(k), where k ranges over the degree (total strengths of connections) values in the network and P(k) is the frequency distribution of k. As a result, when using a single value of β, the total network was scale free (R 2 = 0.89), but with weak average total connectivity (76.45). To correct for this systematic bias, we modified the WGCNA procedure and defined
The parameters β 1 and β 2 were determined independently to allow obtaining scale-free TS and CT networks. We found that values of β 1 = 6 and β 2 = 3 produced approximate scale-free TS (average R 2 = 0.80 and average total TS connectivity 54.10, as before) and CT networks (average R 2 = 0.75 and average total CT connectivity = 17.00, i.e. > 20-fold more cross-tissue edges compared to uniform β = 6) for all tissues and tissue pairs. Using β 1 = 6 and β 2 = 3, the total network remained scale-free (R 2 = 0.88), with a significantly improved average total connectivity (164.40). Considering in each tissue the genes with standard deviation > 0.5 resulted in an adjacency matrix A of size 20,912×20,912 with values A ij ranging from 0 to 1. Finally, we extracted modules out of the co-expression network following the standard WGCNA protocol. Specifically, the adjacency matrix was transformed to a topological overlap matrix (Ravasz et al., 2002) ; coregulated genes were grouped by average linkage hierarchical modeling of the topological overlap matrix; and a dynamic tree cut algorithm was used to cut the modeling dendrogram into gene modules (Langfelder et al., 2008) . This procedure partitioned the 20,912 expression traits into 171 modules with at least 20 gene expression traits; 94 modules were TS (i.e., contained expression traits from only one tissue) whereas 77 modules were CT (i.e., contained expression traits from at least two different tissues) (Table S2 ).
To test the robustness of the identified modules, we repeated the co-expression analysis seven times, each time removing gene expression data from one tissue. For each tissue, we then compared the gene content of the original modules (excluding genes from the removed tissue) to that of the new modules, finding for each original module the new module with the highest percentage overlap. Reassuringly, the original modules that did not contain any genes from the removed tissue were re-identified in the new sets of modules with high fidelity, regardless of whether they were tissue specific or cross tissue [median overlap percentages ranging from 0.82 (after removing SF) to 0.93 (after removing liver)]. As expected, overlap percentages were lower for the original cross tissue modules containing genes from the removed tissue [median overlap percentages ranging from 0.38 (after removing SM) to 0.65 (after removing liver)], and this was particularly true for cross tissue modules dominated by (i.e. contributing the highest number of module genes) the removed tissue [median overlap percentages ranging from 0.05 (after removing VF) to 0.53 (after removing SF)]. Taken together, this analysis demonstrates that crosstissue co-expression network construction identifies co-expression modules that contain genes from subsets of tissues in a manner that is robust against the inclusion or exclusion of data from other tissues, thus supporting the notion that cross-tissue modules reflect bona fide interactions between molecular processes operating in these tissues.
Phenotype Association with Co-expression Modules
To identify modules associated with clinical phenotypes of the STAGE patients, we adopted a multi-step procedure. First, to account for the complexity of the phenotypes of interest (i.e., the extent of atherosclerosis, and plasma metabolism of cholesterol, glucose and systemic inflammation), we considered multiple clinical measurements: For extent of coronary atherosclerosis, we considered two measurements, stenosis score and segment area scores that were determined in preoperative coronary angiograms as described above (Hägg et al., 2009) . For plasma cholesterol and glucose metabolism, we considered four measurements each; plasma, LDL, HDL and VLDL cholesterol levels and HbA1c, blood insulin, proinsulin and fasting blood glucose, respectively. For systemic inflammation we only assessed high sensitive plasma C-reactive protein (CRP) levels. Second to detect both linear and stepwise relations between module expression levels and these 4 main CAD measurements, we used two statistical tests: (i) for a given co-expression module, patients who donated samples to all tissues represented in the module were divided using K-means into the two most distinct patient sets based on the expression levels of the expression traits in that module, and the extent to which quantitative measurements differed between patients in each set was assessed using a ranksum test; (ii) we tested for a non-zero Pearson correlation between the level of the clinical measurement and the first principal component of the data matrix formed by the expression levels of all traits in a given module for the patients who donated samples to all tissues represented in that module (the "module eigengene" (Langfelder and Horvath, 2007) ). Next, for each of the four clinical phenotypes, we combined the P-values for both statistical tests for all respective measurements (i.e., 2 x 2 = 4 P-values (for extent of coronary atherosclerosis), 2 x 4 = 8 P-values (for both plasma cholesterol and glucose metabolism), 2 x 1 = 2 P-values (CRP)) into a single P-value using a weighted data integration method that maximizes the overall statistical power of the combined tests over all modules (Hwang et al., 2005) . Last, to correct for multiple testing, we estimated a positive false discovery rate (FDR) for each P-value in the resulting 171-by-4 table of module-phenotype associations using Storey's method (Storey, 2002) . A FDR threshold of 20% (corresponding to a nominal P-value threshold of 0.03) was used to determine true module-phenotype associations. The individually most significant clinical measurement for each phenotype association was recorded and the association was retained only if the P-value for this measurement was also less than the 0.03 threshold. All computations were performed using the softwares R and Matlab.
Eight of the 14 atherosclerosis modules were dominated by genes from AAW, three from SF, two from VF, and one from SM. Two of the eight AAW-dominated modules were cross-tissue modules (not tissue-specific). Two atherosclerosis modules were also cholesterol modules (modules 37 and 130, both also associated with LDL). There were no combined atherosclerosis/glucose or atherosclerosis/CRP modules. Of 29 cholesterol modules, 26 were dominated (> 90%) by genes from one tissue (SF, VF, SM, or liver). Twenty of the 29 modules were related only to cholesterol. Besides the two modules that were also atherosclerosis modules, two cholesterol modules were also glucose modules and four were also CRP modules. One module was a combined cholesterol, glucose, and CRP module (module 160, related to insulin) ( Figure 2B , Table S2 ).
Ten of the 14 glucose modules were related only to glucose ( Figure 2B , Table S2 ). There was one combined glucose and CRP module (module 105). Six glucose modules were cross-tissue. All 15 CRP modules were tissuespecific; 9 were associated only with CRP ( Figure 2B , Table S2 ). The CRP module most strongly associated with CRP (module 144) was dominated by liver genes (28/29). The other CRP modules were largely present in SM, SF, or VF. In support of the notion that the 61 phenotype-associated modules were more CAD/atherosclerosis-relevant, 1296 previously identified CAD/atherosclerosis-related genes appearing at least once in at least one of the 61 modules represented a higher fraction of the total number of genes than in the 171 modules (40% vs. 33%, p = 1.9 x 10 -29 ).
Assessments of Module Causality Based on Content of CAD Candidate Genes or Enrichment of Module eQTLs in Disease Association According to GWAS
According to the central dogma in molecular biology and as understood in the context of systems genetics, variation in regulatory regions of the genome causes variation in gene expression (RNA expression) that is propagated to downstream genes in signaling pathways that in turn affect other biochemical pathways (Schadt et al., 2005; Schadt, 2009) . With this in mind, we defined "CAD-causal" modules as those either containing one or more of the 53 CAD candidate genes mapped to genome-wide significant (p < 1.0 x 10 -8 ) loci for CAD or modules containing cis-acting expression quantitative trait loci (henceforth "eQTLs") of module genes that were enriched for association with CAD (p < 0.05) using the SNP summary dataset of the case-control CARDIoGRAM metaanalysis of genome-wide associations studies (GWAS) (Deloukas et al., 2013) .
A CAD GWAS SNP is considered causal for CAD for two reasons: (1) because the incidence of CAD is significantly higher among individuals with risk alleles than in those without risk alleles and (2) because genetic variation must precede (be "upstream" of) gene expression and phenotypic variation (the occurrence of CAD cannot alter an individual's genomic sequence), consistent with the basic theme of the central dogma. Consequently, following the GWAS field, we assume that genes in a locus found to be of genome-wide significance for CAD ("CAD candidate genes according to GWAS" or in short "CAD GWA genes") are key genes that cause CAD (i.e., are upstream of CAD) rather than being regulated by CAD (downstream of or reactive to CAD).
However, for other expression traits, the situation is more complicated: CAD can alter gene expression levels (i.e., reactive gene expression or "downstream" gene expression changes), but gene expression can also alter CAD (i.e., causal gene expression or "upstream" gene expression). In other words, if an expression trait (i.e., module) correlates with a phenotype, such as the extent of atherosclerosis, the correlation can reflect either a causal relation, in which gene expression affects the phenotype, or a reactive relation, in which the phenotype alters gene expression. So, when a gene has a cis-eQTL in its regulatory region, it is reasonable to assume that genetic variation at the cis-eQTL causes changes in expression, which in turn alters the phenotype. Thus, gene expression regulated by eQTLs is unlikely to be reactive. Furthermore, we also considered the enrichment of module eQTLs with inherited risk for CAD according to GWAS, as described (Zhong et al., 2010) . Thus, we could ascertain whether a module was causal both from its content of eQTLs and from the enrichment of eQTLs in association with CAD, and thus also indicated to be causal for CAD specifically.
Concretely, the set of eQTLs used to match module genes was that previously calculated from the STAGE cohort (Foroughi Asl et al., 2015) . After matching individual eQTLs to module genes, each set of module eQTLs was first expanded using the 1000 Genomes to include SNPs in strong LD (r 2 > 0.9). The enrichment of CAD association (p < 0.05) according to the CARDIoGRAM meta-analysis dataset of the resulting expanded SNP set was then compared to the average enrichment of CAD association in 10,000 randomized, equal sized and chromosomal distributed SNP sets from the same data. The fold-enrichment was calculated by comparing the number of disease associated SNPs ( ) in the expanded SNP set with the average number of diseaseassociated SNPs in the 10,000 random set ( ̅ ). As the null distributions approximately followed a normal distribution, we defined Z-statistics as follow:
The P-values were calculated from ( , standard normal cumulative probabilities (Zhong et al., 2010; Foroughi Asl et al., 2015) . For modules with less than 10 eQTLs, we instead mapped SNPs of the GWA dataset to a region of ± 500kb of the transcription start or end site of a gene. Next, for G genes in a module, P g for each gene using S mapped SNPs ( ) the CAD association P-value for each gene was calculated using Simes' combination test (Peng et al., 2010) as following:
, where k is the rank of sorted P S . The enrichment of CAD association (p < 0.001) was then calculated as described for eQTLs above.
Using summary datasets for GWAS of plasma levels of CAD risk factors, the same procedures as described for the case-control CARDIoGRAM meta-analysis dataset above, were used to assess i) GWA candidate genes and ii) module eQTL enrichments for associations with CAD risk factors (Teslovich et al., 2010; Dupuis et al., 2010; Soranzo et al., 2010; Strawbridge et al., 2011; The Wellcome Trust Case Control Consortium, 2007) . Similarly, for modules found to be associated with the corresponding STAGE and mouse phenotypes (see section on "Module validation using the Hybrid Mouse Diversity Panel" below), we assessed the mouse eQTLs enrichment in association (p < 0.05) with the extent of mouse aortic root lesion using data from this GWAS of the Hybrid Mouse Diversity Panel (HMDP) (Bennett et al., 2010) . The mouse eQTLs used for this analysis were determined from comparing SNP variation with gene expression in the aortic root lesion of the HMDP. The module eQTL enrichment in association with extent of mouse aortic root lesion (p < 0.05) was calculated as described above.
To test if the risk enrichment scores could be inflated by LD between SNPs belonging to the same gene set defined by each module, we repeated the risk enrichment analysis by adding an LD pruning step after expanding the starting eSNP set using LD statistics. SNPs were pruned in a pairwise fashion every 100 kb at steps of 5 SNPs with a r 2 threshold of 0.9. Of the 18 CAD-associated modules that had eSNPs or SNPs that were enriched with heritable risk according to CARDIoGRAM GWAS (see "risk" column in Figure 2B ), 17 were also found to be enriched after adding the pruning step (all except module 113). In addition, no new modules were found to be risk-enriched after adding the pruning step.
Bayesian Regulatory-Gene Network Reconstruction
Bayesian regulatory-gene networks (RGNs) were inferred taking into account eSNP and other prior information to derive the most probable causal interactions from undirected co-expression associations. Briefly, given a directed acyclic graph (DAG) G between N expression traits, the joint distribution of their expression levels x i (i = 1,...,N) is assumed to take the form
where Pa i denotes the set of parent nodes of node i in the graph G. We further assume that the RGN is a linear Gaussian network (Koller and Friedman, 2009) such that the conditional distributions are given by
where (µ;σ 2 ) denotes a normal probability distribution with mean µ and standard deviation σ. The parameters α i, β i,j and σ i are to be determined along with the graph structure G.
Given a dataset D = (x im ) im of expression levels for N traits in M samples, assumed to be drawn independently from the distribution (1), the likelihood of observing the data given a DAG G is given by
Using Bayes' theorem we can therefore write the likelihood of observing G given the data D as
where P(G) is the prior probability of observing G and Z is a normalization constant. Expression traits with cisacting eQTLs or known transcription factors (TFs) are more likely to act as causal regulators of other expression traits and this information can be encoded in the prior probability P(G) to reconstruct causal networks (Zhu et al., 2004) . Here we imposed a hard prior that only expression traits with eQTLs, GWAS candidate genes or known TFs are allowed to be parents of any other traits (i.e. P(G) = 0 if G contains an edge having a non-eQTL, non-TF or non-GWAS gene as its source node, and constant otherwise). A locally optimal DAG was then found starting from a random graph by randomly adding, removing and reversing edges until the likelihood no longer improves. Maximum-likelihood values for the model parameters α, β and σ are learned along with the graph structure by linearly regressing a node on its current parents.
Because it is computationally and statistically infeasible to reconstruct RGNs with 20,912 nodes (total number of expression traits in the co-expression network) with a hundred samples or less, we imposed an additional constraint in the structure prior P(G), where traits were imposed to take their parent nodes from among traits with which they share a co-expression module. This prior effectively breaks down the 'large' problem of reconstructing a DAG on the entire set of traits to a set of independent 'small' problems of reconstructing a DAG for each coexpression module, and significantly reduces the number of parameters to be estimated from the data.
Here we employed the Bayesian Information Criterion (BIC) to score models and a multiple restart greedy hillclimbing algorithm, using edge additions, deletions, and reversals to search locally optimal DAGs for each coexpression module (Schmidt et al., 2007) .
Algorithm parameters were set to solve 25*N 2 regression problems during each run of the search algorithm, where N is the number of traits in a module. A final consensus causal network was constructed by considering all edges that appeared in 30% or more of the locally optimal DAGs found during each run of the search algorithm. The consensus network was made acyclic by iteratively removing the weakest supported edge from every cycle in the network. Consensus networks for each module are provided in Table S6 .
